Considering the importance of the pleotropic impacts of SMYD2 on cancer biology [15,16,17,18] and the hypothesis that targeting SMYD2 may impair the PC recurrence, the current study reports the novel role of SMYD2 in mCRPC pathogenesis. This evidence concerns the gene SMYD2 and pachyonychia congenita.